Department of Pediatrics

close up of blood vessels
October 25, 2022

Vascular dysfunction during sepsis

Regulation of the enzyme Sirtuin 1 in blood vessel endothelial cells may drive altered metabolism and vascular dysfunction during sepsis, Vanderbilt researchers have discovered.

September 14, 2022

Complementary research, resources, policies improve outcomes for those with substance use disorders: panel

A panel of experts on opioid use disorder (OUD) recently discussed the importance of building recovery ecosystems or networks of resources to respond to the opioid epidemic.

From left are Sarah Jaser, PhD, John Long, MD, Lindsley Long, Rebecca Swan, MD, Steven Webber, MBChB, MRCP, Becky Long, Matt Long, Dan Garry and Emily Garry.
September 8, 2022

Family’s gift supports efforts of three pediatric clinicians

The family of the late William (Bill) Long, MD, made a gift to establish the Dr. William R. Long Fund to support directorships, resident education, fellowships and psychologists in the Department of Pediatrics at Vanderbilt University Medical Center.

September 8, 2022

Juárez named director of behavior analysis

Pablo Juárez, MEd, BCBA, LBA, has been named director of behavior analysis within the Vanderbilt Kennedy Center and the Division of Developmental Medicine at Vanderbilt University Medical Center.

September 7, 2022

VUMC study will evaluate alternative strategies for administering mpox vaccine

Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms.

William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.